Based on 3 Wall Street analysts offering 12 month price targets for RayzeBio, Inc. in the last 3 months. The average price target is $62.50 with a high forecast of $62.50 and a low forecast of $62.50. The average price target represents a 0.02% change from the last price of $62.49.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","30":"$30","41":"$41","52":"$52","63":"$63"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$62.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$62.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$62.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,30,41,52,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.49,62.49076923076923,62.49153846153846,62.49230769230769,62.49307692307693,62.49384615384616,62.494615384615386,62.495384615384616,62.496153846153845,62.496923076923075,62.49769230769231,62.49846153846154,62.49923076923077,{"y":62.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.49,62.49076923076923,62.49153846153846,62.49230769230769,62.49307692307693,62.49384615384616,62.494615384615386,62.495384615384616,62.496153846153845,62.496923076923075,62.49769230769231,62.49846153846154,62.49923076923077,{"y":62.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.49,62.49076923076923,62.49153846153846,62.49230769230769,62.49307692307693,62.49384615384616,62.494615384615386,62.495384615384616,62.496153846153845,62.496923076923075,62.49769230769231,62.49846153846154,62.49923076923077,{"y":62.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.74,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.74,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.74,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.74,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.74,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.74,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.63,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.46,"date":1697155200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.35,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.89,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.98,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.12,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":62.49,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$62.50

Average Price Target$62.50

Lowest Price Target$62.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Downgraded

12/28/23

xxxxxxxxxxxxxxxxxx

Truist Financial

xxxxxxxxxxxxx

Reiterated

12/27/23

xxxxxxxxxxxxxxxxxx

William Blair

xxxxxxxxxxxxx

Downgraded

12/26/23

Michael Yee

Jefferies

$35.00

Buy

-43.99%

Downside

Initiated

10/10/23

Analysts Offer Insights on Healthcare Companies: RayzeBio, Inc. (NASDAQ: RYZB), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Exact Sciences (NASDAQ: EXAS)

Jonathan Miller

Evercore ISI

―

Buy

―

Initiated

10/10/23

RayzeBio's Promising Future: A Buy Rating Based on Unique Radiopharmaceutical Approach and Strategic Growth

Best Analysts Covering RayzeBio, Inc.

Which Analyst Should I Follow If I Want to Buy RYZB and Sell After:

1 Month

Michael YeeJefferies

Success Rate

1/1 ratings generated profit

Average Return

+1.20%

initiated a buy rating 7 months ago

Copying Michael Yee's trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +1.20% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Michael YeeJefferies

Success Rate

1/1 ratings generated profit

Average Return

+210.00%

initiated a buy rating 7 months ago

Copying Michael Yee's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +210.00% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Michael YeeJefferies

Success Rate

1/1 ratings generated profit

Average Return

+212.40%

initiated a buy rating 7 months ago

Copying Michael Yee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +212.40% per trade.

2 Years

Michael YeeJefferies

Success Rate

1/1 ratings generated profit

Average Return

+212.40%

initiated a buy rating 7 months ago

Copying Michael Yee's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +212.40% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RYZB Analyst Recommendation Trends

Rating

Oct 23

Nov 23

Dec 23

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RYZB has received 7 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. RYZB average Analyst price target in the past 3 months is $62.50.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

RYZB Financial Forecast

RYZB Earnings Forecast

Next quarter’s earnings estimate for RYZB is -$0.69 with a range of -$1.62 to -$0.35. The previous quarter’s EPS was -$1.26. RYZB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.81% of the time in the same period. In the last calendar year RYZB has Underperformed its overall industry.

No data currently available

RYZB Sales Forecast

Next quarter’s sales forecast for RYZB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. RYZB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.91% of the time in the same period. In the last calendar year RYZB has Underperformed its overall industry.

RYZB Stock Forecast FAQ

What is RYZB’s average 12-month price target, according to analysts?

Based on analyst ratings, RayzeBio, Inc.’s 12-month average price target is $62.50.

What is RYZB’s upside potential, based on the analysts’ average price target?

RayzeBio, Inc. has 0.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RYZB a Buy, Sell or Hold?

RayzeBio, Inc. has a conensus rating of Hold which is based on 0 buy ratings, 3 hold ratings and 0 sell ratings.

What is RayzeBio, Inc.’s price target?

The average price target for RayzeBio, Inc. is $62.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $62.50 ,the lowest forecast is $62.50. The average price target represents 0.02% Increase from the current price of $62.49.

What do analysts say about RayzeBio, Inc.?

RayzeBio, Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of RYZB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

RayzeBio, Inc. (RYZB) Stock Forecast & Price Target

RYZB Analyst Ratings

RYZB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering RayzeBio, Inc.

RYZB Analyst Recommendation Trends

RYZB Financial Forecast

RYZB Earnings Forecast

RYZB Sales Forecast

RYZB Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts